Is BioRestorative Therapies Stock a Good Investment?
BioRestorative Therapies Investment Advice | BRTX |
- Examine BioRestorative Therapies' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research BioRestorative Therapies' leadership team and their track record. Good management can help BioRestorative Therapies navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact BioRestorative Therapies' business and its evolving consumer preferences.
- Compare BioRestorative Therapies' performance and market position to its competitors. Analyze how BioRestorative Therapies is positioned in terms of product offerings, innovation, and market share.
- Check if BioRestorative Therapies pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about BioRestorative Therapies' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in BioRestorative Therapies stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if BioRestorative Therapies is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine BioRestorative Therapies Stock
Researching BioRestorative Therapies' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 27.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.02. Some equities with similar Price to Book (P/B) outperform the market in the long run. BioRestorative Therapies recorded a loss per share of 2.38. The entity had not issued any dividends in recent years. The firm had 1:4000 split on the 27th of October 2021.
To determine if BioRestorative Therapies is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding BioRestorative Therapies' research are outlined below:
BioRestorative Therapies generated a negative expected return over the last 90 days | |
BioRestorative Therapies may become a speculative penny stock | |
BioRestorative Therapies has high historical volatility and very poor performance | |
BioRestorative Therapies has high likelihood to experience some financial distress in the next 2 years | |
The company reported the previous year's revenue of 145.8 K. Net Loss for the year was (10.42 M) with profit before overhead, payroll, taxes, and interest of 119.8 K. | |
BioRestorative Therapies currently holds about 17.93 M in cash with (6.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.92, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
BioRestorative Therapies has a poor financial position based on the latest SEC disclosures | |
Roughly 27.0% of the company shares are held by company insiders | |
Latest headline from benzinga.com: BioRestorative Ends Q3 In Strong Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial |
BioRestorative Therapies uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in BioRestorative Therapies. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to BioRestorative Therapies' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
12th of February 2024 Upcoming Quarterly Report | View | |
10th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
12th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact BioRestorative Therapies' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises BioRestorative Therapies' investors have experienced.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-08-13 | 2024-06-30 | -0.56 | -0.5 | 0.06 | 10 | ||
2024-03-18 | 2023-12-31 | -0.69 | -0.57 | 0.12 | 17 | ||
2022-11-14 | 2022-09-30 | -1.45 | -1.28 | 0.17 | 11 | ||
2024-06-11 | 2024-03-31 | -0.52 | -0.33 | 0.19 | 36 | ||
2023-03-27 | 2022-12-31 | -1.43 | -1.19 | 0.24 | 16 | ||
2023-05-12 | 2023-03-31 | -1.26 | -1.53 | -0.27 | 21 | ||
2023-08-11 | 2023-06-30 | -1.19 | -0.77 | 0.42 | 35 | ||
2024-11-11 | 2024-09-30 | -0.43 | -0.0068 | 0.4232 | 98 |
Know BioRestorative Therapies' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioRestorative Therapies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioRestorative Therapies backward and forwards among themselves. BioRestorative Therapies' institutional investor refers to the entity that pools money to purchase BioRestorative Therapies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Tower Research Capital Llc | 2024-09-30 | 2.2 K | Ubs Group Ag | 2024-09-30 | 693 | Bank Of America Corp | 2024-09-30 | 42.0 | Td Waterhouse Canada Inc | 2024-09-30 | 2.0 | Jjj Advisors Inc | 2024-06-30 | 1.0 | Wells Fargo & Co | 2024-09-30 | 0.0 | Sabby Management Llc | 2024-06-30 | 0.0 | Two Sigma Investments Llc | 2024-06-30 | 0.0 | Geode Capital Management, Llc | 2024-09-30 | 55.7 K | Stonex Group Inc | 2024-09-30 | 50.1 K | Wealth Alliance, Llc | 2024-09-30 | 40 K |
BioRestorative Therapies' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.1 M.Market Cap |
|
BioRestorative Therapies' profitablity analysis
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.88) | (0.92) | |
Return On Capital Employed | (1.52) | (1.45) | |
Return On Assets | (0.83) | (0.87) | |
Return On Equity | (1.04) | (0.99) |
Determining BioRestorative Therapies' profitability involves analyzing its financial statements and using various financial metrics to determine if BioRestorative Therapies is a good buy. For example, gross profit margin measures BioRestorative Therapies' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of BioRestorative Therapies' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in BioRestorative Therapies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BioRestorative Therapies. Check BioRestorative Therapies' Beneish M Score to see the likelihood of BioRestorative Therapies' management manipulating its earnings.
Evaluate BioRestorative Therapies' management efficiency
BioRestorative Therapies has return on total asset (ROA) of (0.5324) % which means that it has lost $0.5324 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1712) %, meaning that it created substantial loss on money invested by shareholders. BioRestorative Therapies' management efficiency ratios could be used to measure how well BioRestorative Therapies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.92 in 2024. Return On Capital Employed is likely to rise to -1.45 in 2024. At this time, BioRestorative Therapies' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 320.5 K in 2024, despite the fact that Non Currrent Assets Other are likely to grow to (842.6 K).Last Reported | Projected for Next Year | ||
Book Value Per Share | 2.37 | 2.49 | |
Tangible Book Value Per Share | 2.20 | 2.31 | |
Enterprise Value Over EBITDA | (0.44) | (0.46) | |
Price Book Value Ratio | 0.73 | 0.77 | |
Enterprise Value Multiple | (0.44) | (0.46) | |
Price Fair Value | 0.73 | 0.77 | |
Enterprise Value | 6.6 M | 4.5 M |
Understanding the operational decisions made by BioRestorative Therapies management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 62.823 |
Basic technical analysis of BioRestorative Stock
As of the 12th of December 2024, BioRestorative Therapies shows the Mean Deviation of 2.66, risk adjusted performance of 0.0199, and Downside Deviation of 3.7. BioRestorative Therapies technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.BioRestorative Therapies' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioRestorative Therapies insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioRestorative Therapies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioRestorative Therapies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BioRestorative Therapies' Outstanding Corporate Bonds
BioRestorative Therapies issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioRestorative Therapies uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioRestorative bonds can be classified according to their maturity, which is the date when BioRestorative Therapies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Volcan Compania Minera Corp BondUSP98047AC08 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
MPLX LP 4875 Corp BondUS55336VAG59 | View | |
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
BIOGEN INC 52 Corp BondUS09062XAD57 | View | |
BIOGEN INC 405 Corp BondUS09062XAF06 | View |
Understand BioRestorative Therapies' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing BioRestorative Therapies' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
Risk Adjusted Performance | 0.0199 | |||
Market Risk Adjusted Performance | 0.038 | |||
Mean Deviation | 2.66 | |||
Semi Deviation | 3.31 | |||
Downside Deviation | 3.7 | |||
Coefficient Of Variation | 6171.42 | |||
Standard Deviation | 3.92 | |||
Variance | 15.37 | |||
Information Ratio | (0.02) | |||
Jensen Alpha | (0.17) | |||
Total Risk Alpha | (0.57) | |||
Sortino Ratio | (0.02) | |||
Treynor Ratio | 0.028 | |||
Maximum Drawdown | 24.86 | |||
Value At Risk | (6.10) | |||
Potential Upside | 6.45 | |||
Downside Variance | 13.66 | |||
Semi Variance | 10.94 | |||
Expected Short fall | (3.09) | |||
Skewness | 1.1 | |||
Kurtosis | 4.36 |
Risk Adjusted Performance | 0.0199 | |||
Market Risk Adjusted Performance | 0.038 | |||
Mean Deviation | 2.66 | |||
Semi Deviation | 3.31 | |||
Downside Deviation | 3.7 | |||
Coefficient Of Variation | 6171.42 | |||
Standard Deviation | 3.92 | |||
Variance | 15.37 | |||
Information Ratio | (0.02) | |||
Jensen Alpha | (0.17) | |||
Total Risk Alpha | (0.57) | |||
Sortino Ratio | (0.02) | |||
Treynor Ratio | 0.028 | |||
Maximum Drawdown | 24.86 | |||
Value At Risk | (6.10) | |||
Potential Upside | 6.45 | |||
Downside Variance | 13.66 | |||
Semi Variance | 10.94 | |||
Expected Short fall | (3.09) | |||
Skewness | 1.1 | |||
Kurtosis | 4.36 |
Consider BioRestorative Therapies' intraday indicators
BioRestorative Therapies intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioRestorative Therapies stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Daily Balance Of Power | (9,223,372,036,855) | |||
Rate Of Daily Change | 0.99 | |||
Day Median Price | 1.46 | |||
Day Typical Price | 1.46 | |||
Price Action Indicator | (0.01) | |||
Period Momentum Indicator | (0.01) |
BioRestorative Stock media impact
Far too much social signal, news, headlines, and media speculation about BioRestorative Therapies that are available to investors today. That information is available publicly through BioRestorative media outlets and privately through word of mouth or via BioRestorative internal channels. However, regardless of the origin, that massive amount of BioRestorative data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of BioRestorative Therapies news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioRestorative Therapies relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioRestorative Therapies' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioRestorative Therapies alpha.
BioRestorative Therapies Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards BioRestorative Therapies can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BioRestorative Therapies Corporate Management
Francisco Silva | VP Scientist | Profile | |
Robert Paccasassi | Vice Compliance | Profile | |
Stephen Kilmer | Investor Officer | Profile | |
Wayne MD | Clinical Board | Profile | |
Robert Kristal | Chief Officer | Profile |
Additional Tools for BioRestorative Stock Analysis
When running BioRestorative Therapies' price analysis, check to measure BioRestorative Therapies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioRestorative Therapies is operating at the current time. Most of BioRestorative Therapies' value examination focuses on studying past and present price action to predict the probability of BioRestorative Therapies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioRestorative Therapies' price. Additionally, you may evaluate how the addition of BioRestorative Therapies to your portfolios can decrease your overall portfolio volatility.